Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.06. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
15.05. | Acrivon Therapeutics GAAP EPS of -$0.51 beats by $0.10 | 3 | Seeking Alpha | ||
15.05. | Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock | 2 | Investing.com | ||
14.05. | Acrivon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
14.05. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 563 | GlobeNewswire (Europe) | Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of... ► Artikel lesen | |
ACRIVON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
05.05. | Piper Sandler sets $6 target for Acrivon stock, rates it Overweight | 1 | Investing.com | ||
25.04. | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 | 2 | GlobeNewswire (USA) | ||
07.04. | Acrivon appoints new chief medical officer to advance cancer trials | 1 | Investing.com | ||
07.04. | Acrivon ernennt neuen medizinischen Leiter zur Förderung von Krebsstudien | 2 | Investing.com Deutsch | ||
07.04. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer | 139 | GlobeNewswire (Europe) | Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of... ► Artikel lesen | |
07.04. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
28.03. | Acrivon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
28.03. | H.C. Wainwright maintains Acrivon stock Buy rating, $19 target | 2 | Investing.com | ||
28.03. | Acrivon Therapeutics reports Q4 results | 6 | Seeking Alpha | ||
27.03. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results | 167 | GlobeNewswire (Europe) | Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects R&D event highlighted positive... ► Artikel lesen | |
27.03. | Acrivon Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
26.03. | Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright | 7 | Investing.com | ||
26.03. | Cantor Fitzgerald maintains Overweight on Acrivon stock | 3 | Investing.com | ||
26.03. | Acrivon stops developing Lilly castoff for ovarian and bladder cancers to switch focus to endometrial | 8 | FierceBiotech | ||
26.03. | JMP maintains Acrivon stock with $17 target following update | 3 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 95,65 | -0,36 % | Wochenvorschau 32: August-Highlights: Von Biontech bis Munich Re - die Wirtschaftswoche | Die Woche vom 4. bis 8. August bringt Highlights von Biontech, Infineon und Siemens bis hin zu Allianz und Munich Re - begleitet von zentralen Konjunktursignalen weltweit.Die Woche vom 4. bis 8. August... ► Artikel lesen | |
CUREVAC | 4,680 | -0,68 % | CureVac Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
AMGEN | 244,70 | -5,72 % | Prognose-Schock vs. Prognose-Boost - Zalando, Fresenius, Beiersdorf, Qiagen, Super Micro, AMD, Amgen | Der DAX hat sich gestern erneut gut geschlagen und an die starke Performance vom Montag angeknüpft. Es gab zwar die eine oder andere Schwächephase. Trotzdem schloss der DAX 0,37 Prozent höher bei 23.846... ► Artikel lesen | |
NOVAVAX | 6,450 | +10,65 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
BIOGEN | 111,15 | -3,26 % | Biogen-Aktie: Kurs mit wenig Bewegung (114,5994 €) | Im US-amerikanischen Wertpapierhandel ist das Wertpapier von Biogen derzeit unauffällig. Die Aktie kostete zuletzt 132,69 US-Dollar. Ein geringes Kursplus von 0,38 Prozent zeigt die Kurstafel für die... ► Artikel lesen | |
MAINZ BIOMED | 1,480 | -1,99 % | Mainz BioMed NV: Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants | BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
VIKING THERAPEUTICS | 26,945 | -8,33 % | Is Viking Therapeutics the Next Big Biotech Bet? | ||
INTELLIA THERAPEUTICS | 9,700 | -2,92 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
GENMAB | 181,75 | -5,07 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2025 | Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 7,380 | +2,07 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
TEMPUS AI | 47,600 | -4,80 % | If You'd Invested $1,000 in Tempus AI Stock (TEM) 1 Year Ago, Here's How Much You'd Have Today | ||
SAREPTA THERAPEUTICS | 13,970 | -3,42 % | Sarepta-Aktie: +87,8% über Nacht - Sharedeals-Leser feiern | Bei Sarepta Therapeutics explodiert der Kurs innerhalb von wenigen Stunden nach einem exklusiven Tipp auf sharedeals.de. Was steckt hinter dem Coup - und wie findest Du den nächsten Depot-Turbo? Gideon... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 0,920 | -20,96 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx in Acute Myocarditis | Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx over placebo.Reduction in ECV was associated with improvements... ► Artikel lesen | |
EXELIXIS | 32,290 | -0,22 % | Exelixis, Inc.: Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors | - Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,178 | -3,70 % | Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models |